The BSAC Respiratory Resistance Surveillance Programme
Long-term Surveillance of the in vitro Activity of a Range of Antimicrobial Agents
Against Potential Pathogens Isolated from Lower Respiratory Sources
of Patients with Lower Respiratory Tract Infections

Respiratory Protocol 2013-14
version 1 - 19th August 2014
applies to the Isolate Collection Period from 1st October 2013 to 30th September 2014
supersedes Protocol version 5.1 of 29th May 2014 (for the same Isolate Collection Period)

CONTENTS

1  Summary
2  Selection, Collection and Transport of Isolates
3  Additional Data to be supplied with Isolates
4  Identification and Storage of Isolates
5  Susceptibility Testing of Isolates
6  Antimicrobial Agents for Testing
7  Detection of Mechanisms of Resistance and Related Issues of Testing
8  Quality Assurance
9  Data Handling
10 Collecting Laboratories
11 Protocol Amendments
Summary

Study Title:
BSAC Respiratory Resistance Surveillance Programme

Initiator:
British Society for Antimicrobial Chemotherapy.

Funding:
The study will normally be funded by sponsorship from two or more pharmaceutical companies.

Objective:
Determination of the antimicrobial susceptibility of currently circulating lower respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis from suspected community-onset infections, and Staphylococcus aureus, Pseudomonas spp., Acinetobacter spp. and Enterobacteriaceae from clinically significant hospital-onset infections.

Central Testing Laboratory:

Geographical Scope:
Forty collecting centres have been or will be selected to give good geographical spread throughout the United Kingdom and Ireland. The number of centres may be reduced and the target number of isolates per centre increased in future if more centres merge and the population they cover increases.

Selection and Numbers of Isolates:
Three groups of organisms will be collected from the lower respiratory tract of patients with suspected community-onset lower respiratory tract infection: Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.

Four groups of organisms will be collected from the lower respiratory tract of patients with clinically significant hospital-onset lower respiratory tract infection: Staphylococcus aureus, Pseudomonas spp., Acinetobacter spp. and Enterobacteriaceae.

Isolates from patients with cystic fibrosis are excluded, as are repeat isolates within 14 days, which are assumed to be from the same episode of infection.

The period for collection of isolates each season will be 1st October to 30th September.

Each centre will collect up to 14 consecutive isolates of S. pneumoniae and H. influenzae (giving a target total of 560 of each species); 7 consecutive isolates of M. catarrhalis, S. aureus, Pseudomonas spp. and Acinetobacter spp. (target total 280 each); and 28 consecutive isolates of Enterobacteriaceae (target total 1120).

Testing of Isolates:
The isolates will be re-identified by the Central Testing Laboratory and tested using the BSAC agar dilution method for the determination of minimum inhibitory concentration. Further tests will be used to identify selected mechanisms of resistance and to type selected groups of organisms.

2 Selection, Collection and Transport of Isolates

2.1 Population
The population for study is all patients with suspected community-onset lower respiratory infection or clinically significant hospital-onset lower respiratory tract infection.

Infections are considered to be hospital-onset if the first non-duplicate sample positive for the organism of interest was taken more than 48 hours after hospital admission and while the patient remained a hospital inpatient, and community-onset otherwise.

2.2 Organisms
Each centre will collect consecutive isolates of the organisms shown in the table below, up to the number shown, and according to the following criteria:

<table>
<thead>
<tr>
<th>From community-onset infections</th>
<th>N</th>
<th>From hospital-onset infections</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>Streptococcus pneumoniae</td>
<td>14</td>
<td>Staphylococcus aureus</td>
<td>7</td>
</tr>
<tr>
<td>Haemophilus influenzae</td>
<td>14</td>
<td>Pseudomonas spp.</td>
<td>7</td>
</tr>
<tr>
<td>Moraxella catarrhalis</td>
<td>14</td>
<td>Acinetobacter spp.</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Enterobacteriaceae*</td>
<td>28</td>
</tr>
</tbody>
</table>
**Inclusion Criteria:**
1. Isolates from lower respiratory tract samples.
2. Patients with suspected community-onset lower respiratory tract infections or hospital-onset lower respiratory tract infections judged clinically significant by the responsible medical microbiologist.
3. Isolates collected between 1<sup>st</sup> October and 30<sup>th</sup> September.

**Exclusion Criteria:**
1. Repeat isolates from the same infection episode i.e. isolates obtained within two weeks of a previous isolation of the same species from a clinically-significant hospital-onset or suspected community-onset lower respiratory tract infection in the same patient. (Note that isolates of different species collected from the same clinical episode are not excluded.)
2. Patient having cystic fibrosis.
3a. Hospital inpatient admitted more than 48 hours before the sample was taken (for community-onset infections).
3b. Not a hospital inpatient or admitted 48 hours or less before the sample was taken (for hospital-onset infections).

* Enterobacteriaceae will be collected as unspeciated ‘coliforms’ and identified to genus (and normally to species) level centrally. They will be tested according to the methods described below. For practical reasons related to their swarming behaviour, Proteae may be stored initially and tested at intervals when sufficient numbers are available.

**Discrepant Identifications, Over-Quota Isolates, and Mixed Cultures**
1. In general, an isolate will be excluded if central and collecting laboratory identifications place it in different organism collection groups, and will remain eligible for inclusion (under its central laboratory identification) if both laboratories place it in the same collection group. Gram-negative bacilli other than *Pseudomonas* form a single collection group for this purpose. Replacements for excluded isolates will be sought, up to the quota, if time remains in the collecting season.

2. If a collecting laboratory submits more than the quota of 7, 14 or 28 isolates of a defined collection group, excess isolates will be excluded starting with any that were submitted under other names and then by date of collection (latest first).

3. In cases of mild, obvious and understandable contamination e.g. an isolate predominantly of *E. coli* with a small number of coagulase-negative staphylococci, attempts will be made to re-isolate and include the primary organism e.g. *E. coli*. Cultures that are grossly mixed, or that are mixtures of organisms from the same group, will be discarded and, if time remains in the collecting season, a replacement will be sought.

**2.3 Storage of Isolates in Collecting Laboratories**
Isolates may be stored frozen in suitable media at or below -70°C for up to 12 months, or at temperatures up to -20°C for shorter periods compatible with very high rates of recovery of viable organisms (no more than 2 months for *S. pneumoniae* and *H. influenzae*). Thawed isolates will be sub-cultured onto non-selective medium to give luxuriant growth after overnight incubation before being prepared for transport to the Central Testing Laboratory.

**2.4 Transport**
Collecting laboratories will send isolates to the Central Testing Laboratory on agar slopes or by any other suitable method, and in compliance with prevailing transport regulations.

**3 Additional Data to be Supplied By or About Collecting Laboratories**
For each isolate, the following information will be supplied by the collecting laboratory:
- Date of specimen collection
- Age of patient
- Sex of patient
- Care setting of patient, from the following categories:
  - community (GP) or outpatient
  - hospital inpatient (≤48 hours from admission)
  - hospital inpatient (>48 hours from admission)
- Specimen type, from the following categories:
  - sputum
  - broncho-alveolar lavage
  - tracheal/endotracheal aspirate or secretions
  - other confirmed lower respiratory tract, to be specified
- For hospital-onset isolates, the requesting speciality, from the following categories:
  - accident & emergency
  - intensive care unit (not including high dependency unit)
  - high dependency unit
  - surgical
  - cardiology
• haematology / oncology
• nephrology / renal unit
• respiratory medicine
• care of the elderly
• paediatrics
• medical admissions/medical assessment unit
• general medical
• other

- For hospital-onset isolates, time in hospital before sample collection, if known.
- For hospital-onset isolates, ventilator status: ventilated, not ventilated, ventilation status unknown
- Identification of isolate by genus and species, if known
- The collecting laboratory’s own antimicrobial susceptibility test results.

For those collecting laboratories that contribute to Public Health England’s voluntary respiratory tract infection surveillance, the Central Testing Laboratory will also collect and supply summary information about clinically significant lower respiratory tract infection from that scheme or other sources. At minimum, this information will include (for each genus and species included in the BSAC Respiratory Resistance Surveillance Programme and covered by the PHE scheme for the same setting i.e. hospital- or community-onset) the total number collected by each laboratory, excluding repeat isolates within two weeks or other de-duplication period defined by the scheme.

## 4 Identification and Storage of Isolates

### 4.1 Receipt

On receipt at the Central Testing Laboratory, the isolates will be subcultured on appropriate non-selective medium and checked for purity. Following identification, isolates not conforming to the criteria of section 2 above will be discarded without testing.

### 4.2 Initial Identification

The isolates will be identified by appropriate methods as detailed below. Organisms will be identified to species level in the large majority of cases, with occasional exceptions for particularly unusual species, which may be reported as genus spp.

MALDI-ToF will be used for the majority of isolates, with identification to species level in most cases. The following groups are expected to be identified by MALDI-ToF:
- *H. influenzae*
- *M. catarrhalis*
- Enterobacteriaceae other than *E. coli*
- *Pseudomonas*
- Staphylococci (in conjunction with CHROMagar)

The following groups will be identified by the methods listed below:
- *S. pneumoniae*: with ID32 STREP kits and additional biochemical tests for definitive speciation by the PHE Respiratory and Vaccine-Preventable Bacteria Reference Unit (RVPBRU)
- *E. coli*: Pink on UTI medium or CHROMagar
- *Acinetobacter*: blaOXA-51 PCR to detect *A. baumannii*. If negative, then API20 NE strips.

MALDI-ToF may be used as an alternative for *E. coli*. MALDI-ToF will not be used for *S. pneumoniae* or *Acinetobacter* until it has been further developed to improve its reliability for these organisms and its use is approved by the BSAC Working Party. Coagulase tests may be used as an alternative to MALDI-ToF for staphylococci.

### 4.3 Further Identification

Serotypes of *S. pneumoniae* will be determined by the standard methods of RVPBRU, comprising either classical serotyping or prediction from genomic sequence data.

Isolates that give doubtful or unusual results or exhibit antibiograms that are anomalous for their species identification will be re-identified by a second method, generally by testing growth factor X and V dependence for *H. influenzae*, rpoB PCR and sequencing for *Acinetobacter*, biochemical tests at the identification section of AMRHAI for *M. catarrhalis*, API20 E or API20 NE strips for *Pseudomonas* and Enterobacteriaceae and MALDI-ToF for staphylococci.

### 4.4 Storage

Isolates will be stored at or below –70°C using blood glycerol broth or other agreed established methods that are known to give a high probability of long-term recovery of viable organisms.
**5 Susceptibility Testing of Isolates**


Future BSAC amendments to the original descriptions may be incorporated.

<table>
<thead>
<tr>
<th>Organism</th>
<th>Medium</th>
<th>Supplements</th>
<th>Spot size (CFU/spot)</th>
<th>Atmosphere</th>
<th>Temperature &amp; duration</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>S. pneumoniae</em></td>
<td>Iso-Sensitest agar</td>
<td>5% defibrinated horse blood</td>
<td>$10^4$</td>
<td>air plus 4–6% CO$_2$</td>
<td>35–37°C 18–20 hours</td>
</tr>
<tr>
<td>Staphylococci (tests other than oxacillin)</td>
<td>Iso-Sensitest agar</td>
<td>None</td>
<td>$10^4$ ($10^6$ against penicillin)</td>
<td>air</td>
<td>35–37°C 18–20 hours</td>
</tr>
<tr>
<td>Staphylococci (oxacillin)</td>
<td>Columbia agar</td>
<td>2% NaCl</td>
<td>$10^4$</td>
<td>air</td>
<td>30°C 24 hours</td>
</tr>
<tr>
<td>Enterobacteriaceae (excluding swarming species)</td>
<td>Iso-Sensitest agar</td>
<td>None</td>
<td>$10^4$</td>
<td>air</td>
<td>35–37°C 18–20 hours</td>
</tr>
<tr>
<td>swarming Enterobacteriaceae e.g. Proteus spp.</td>
<td>Iso-Sensitest agar</td>
<td>50 mg/L PNPG</td>
<td>$10^4$</td>
<td>air</td>
<td>35–37°C 18–20 hours</td>
</tr>
<tr>
<td>Acinetobacter spp.</td>
<td>Iso-Sensitest agar</td>
<td>None</td>
<td>$10^4$</td>
<td>air</td>
<td>35–37°C 18–20 hours</td>
</tr>
<tr>
<td>Pseudomonas spp.</td>
<td>Iso-Sensitest agar</td>
<td>None</td>
<td>$10^4$</td>
<td>air</td>
<td>35–37°C 18–20 hours</td>
</tr>
<tr>
<td><em>H. influenzae</em></td>
<td>Iso-Sensitest agar</td>
<td>5% defibrinated horse blood</td>
<td>$10^4$</td>
<td>air plus 4–6% CO2</td>
<td>35–37°C 18–20 hours</td>
</tr>
<tr>
<td><em>M. catarrhalis</em></td>
<td>Iso-Sensitest agar</td>
<td>5% defibrinated horse blood</td>
<td>$10^4$ ($10^6$ against β-lactams)</td>
<td>air</td>
<td>35–37°C 18–20 hours</td>
</tr>
</tbody>
</table>

Special conditions may apply for other antimicrobials not included in the continuity group, for example Ca$^{2+}$-supplemented isotonic medium for daptomycin.

As Proteae require anti-swarming measures and therefore cannot be tested on the same plates as other Enterobacteriaceae, the testing of Proteae may be delayed until a sufficient number have been collected to justify a special run of MIC tests.
6 Antimicrobial Agents for Testing - Testing Ranges and Interpretation

The isolates will be tested against a range of antimicrobial agents. The tests and agents listed below form the 'continuity group' and are intended to be studied for the full term of the programme. Additional agents may also be tested.

The concentration ranges tabulated below are the planned initial testing ranges. In some cases, extended ranges (shown in brackets) will be tested if the initial range does not identify the MIC exactly. The ranges are intended to be wide enough to give full endpoints and avoid off-scale values in almost all cases. If not, MICs censored at the upper end of the range will be listed initially as 'greater than the highest tested concentration', which may be translated to 'greater than or equal to twice the highest tested concentration' in published tables. MICs censored at the lower end of the range will be listed as 'less than or equal to the lowest tested concentration'.

**Gram-positive isolates - community-onset S. pneumoniae**

<table>
<thead>
<tr>
<th>DRUG</th>
<th>S. pneumoniae mg/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>amoxicillin</td>
<td>0.004–16</td>
</tr>
<tr>
<td>cefotaxime</td>
<td>0.004–4</td>
</tr>
<tr>
<td>cefuroxime</td>
<td>0.002–8</td>
</tr>
<tr>
<td>ciprofloxacin</td>
<td>0.25–128</td>
</tr>
<tr>
<td>clindamycin</td>
<td>0.015–128</td>
</tr>
<tr>
<td>clindamycin–erythromycin</td>
<td>0.5 cli + 4 ery</td>
</tr>
<tr>
<td>erythromycin</td>
<td>0.015–128</td>
</tr>
<tr>
<td>penicillin</td>
<td>0.002–16</td>
</tr>
<tr>
<td>tetracycline</td>
<td>0.03–128</td>
</tr>
<tr>
<td>trimethoprim</td>
<td>0.06–128</td>
</tr>
</tbody>
</table>

**Gram-positive isolates - hospital-onset S. aureus**

<table>
<thead>
<tr>
<th>DRUG</th>
<th>S. aureus mg/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>ciprofloxacin</td>
<td>0.03–128</td>
</tr>
<tr>
<td>clindamycin</td>
<td>0.03–128</td>
</tr>
<tr>
<td>clindamycin–erythromycin</td>
<td>0.5 cli + 4 ery</td>
</tr>
<tr>
<td>erythromycin</td>
<td>0.03–128</td>
</tr>
<tr>
<td>fusidic acid</td>
<td>0.015–256</td>
</tr>
<tr>
<td>gentamicin</td>
<td>0.008–128</td>
</tr>
<tr>
<td>minocycline</td>
<td>0.015–2 (~32)</td>
</tr>
<tr>
<td>mupirocin</td>
<td>0.06–1024</td>
</tr>
<tr>
<td>oxacillin</td>
<td>0.03–128</td>
</tr>
<tr>
<td>penicillin</td>
<td>0.015–64</td>
</tr>
<tr>
<td>rifampicin</td>
<td>0.004–2 (ST)</td>
</tr>
<tr>
<td></td>
<td>0.004–256 (CN)</td>
</tr>
<tr>
<td>telcoplanin</td>
<td>0.06–16</td>
</tr>
<tr>
<td>tetracycline</td>
<td>0.06–128</td>
</tr>
<tr>
<td>trimethoprim</td>
<td>0.06–128</td>
</tr>
<tr>
<td>vancomycin</td>
<td>0.25–16</td>
</tr>
</tbody>
</table>

1 This is a breakpoint test to identify inducible resistance to clindamycin.
<table>
<thead>
<tr>
<th>DRUG</th>
<th>Enterobacteriaceae mg/L</th>
<th>Pseudomonas mg/L</th>
<th>Acinetobacter mg/L</th>
<th>H. influenzae mg/L</th>
<th>M. catarrhalis mg/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>amoxicillin</td>
<td>0.25–256</td>
<td></td>
<td></td>
<td>0.015–256</td>
<td></td>
</tr>
<tr>
<td>amoxicillin-clavulanate¹</td>
<td>0.12–64</td>
<td></td>
<td></td>
<td>0.015–8</td>
<td>0.001–2 (*8)</td>
</tr>
<tr>
<td>ampicillin</td>
<td></td>
<td></td>
<td></td>
<td>0.015–256</td>
<td></td>
</tr>
<tr>
<td>carbenicillin</td>
<td></td>
<td></td>
<td></td>
<td>0.015–256</td>
<td></td>
</tr>
<tr>
<td>cefotaxime</td>
<td>0.008–16 (*256)</td>
<td></td>
<td>8–512</td>
<td>0.001–1</td>
<td></td>
</tr>
<tr>
<td>cefoxitin</td>
<td>0.5–128</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ceftriaxime</td>
<td>0.008–16 (*256)</td>
<td>0.03–16 (*256)</td>
<td>0.12–16 (*256)</td>
<td>0.015–32</td>
<td>0.03–32</td>
</tr>
<tr>
<td>cefuroxime</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ciprofloxacin</td>
<td>0.002–16 (*256)</td>
<td>0.002–16 (*256)</td>
<td>0.002–16 (*256)</td>
<td>0.001–8 (*32)</td>
<td>0.004–4</td>
</tr>
<tr>
<td>colistin²</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>erythromycin</td>
<td>0.12–16 (*256)</td>
<td>0.12–16 (*256)</td>
<td>0.12–16 (*0.015, 256)</td>
<td>0.03–256</td>
<td>0.004–4</td>
</tr>
<tr>
<td>gentamicin²</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>meropenem³</td>
<td>0.004–2 (*256)</td>
<td>0.03–32</td>
<td>0.03–64 (*256)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>nalidixic acidowered</td>
<td></td>
<td></td>
<td></td>
<td>0.25–128</td>
<td>0.25–128</td>
</tr>
<tr>
<td>piperacillin-tazobactam⁶</td>
<td>0.015–256 [*32 (P)]</td>
<td>0.12–64 (*256)</td>
<td>0.12–64 (*256)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>tazobactam⁷</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tetracycline</td>
<td>0.12–128</td>
<td></td>
<td></td>
<td>0.03–32</td>
<td>0.03–8</td>
</tr>
<tr>
<td>tobramycin</td>
<td>0.12–16 (*256)</td>
<td>0.12–16 (*256)</td>
<td>0.12–16 (*0.015, 256)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>trimethoprim</td>
<td></td>
<td></td>
<td></td>
<td>0.002–256</td>
<td></td>
</tr>
</tbody>
</table>

¹ This is a breakpoint test to identify inducible resistance to clindamycin.
² Test with clavulanate at 2 mg/L fixed concentration; reported concentrations refer to amoxicillin.
³ Excluding Serratia and Proteae.
⁴ Full range for colistin tested in first run as colistin resistance is suspected to be unstable.
⁵ Poor stability: plates containing these agents to be used on day of preparation.
⁶ Test with tazobactam at 4 mg/L fixed concentration; reported concentrations refer to piperacillin.
⁷ This is a breakpoint test to assist with interpretation of piperacillin-tazobactam MICs for Acinetobacter, where 4mg/L tazobactam may be inhibitory in its own right.
⁸ Nalidixic acid MICs to be tested over this range for one year only, in preparation for defining a single concentration to use in place of previous 30µg disc test.

(*) Extend range as shown in brackets if MIC is outside the initial range tested.
(CN) coagulase-negative staphylococci; (P) Proteae; (ST) S. aureus.

Interpretation of MICs

Categorisation
If isolates are to be categorised as susceptible/intermediate/resistant, the BSAC breakpoints current at the time (www.bsac.org.uk) will be used or, in the absence of BSAC guidance, EUCAST breakpoints (www.eucast.org).

Inconsistencies between Initial and Subsequent MIC Tests
On rare occasions, an isolate may show very different MICs in initial and subsequent tests. For example, a highly cefotaxime-resistant isolate may be found to be ceftoxime susceptible when later re-tested to ascertain ESBL status. This could be the result of a plasmid loss, which may also affect susceptibility to other antimicrobial agents not included in the re-test panel. If such a loss is inferred, the isolate will be retained in the dataset with its originally determined MICs, and its ESBL status will be recorded as not confirmed.

7 Further Testing - Detection of Mechanisms of Resistance and Additional Typing

7.1 Planned Further Phenotypic Testing

β-Lactamase production
All isolates of H. influenzae and M. catarrhalis will be tested with for β-lactamase with the chromogenic cephalosporin nitrocefin.

Extended-spectrum β-lactamases (ESBLs), AmpC enzymes and K1 hyperproduction
All isolates of Enterobacteriaceae with ceftazidime or cefotaxime MICs on or above the susceptibility breakpoint (i.e. ≥1 mg/L), and isolates of Klebsiella oxytoca with piperacillin-tazobactam MICs ≥128 mg/L, will be tested further (by BSAC agar dilution or Etest):
- For ESBL activity - using the clavulanate synergy test with ceftazidime, cefotaxime and cefepime each ± 4 mg/L clavulanate. Cefpirome is an acceptable substitute for cefepime when cefepime is unavailable.
- For AmpC activity - using the cloxacillin synergy test with cefotaxime ± 100 mg/l cloxacillin for BSAC agar dilution or with cefotetan ± cloxacillin for Etest.
• In addition, isolates of *K. oxytoca* with piperacillin-tazobactam MICs ≥128 mg/L will be tested against aztreonam and cefturoxime for detection of K1 hyperproduction by interpretive reading.

ESBL production is inferred if any (but generally all) of the three cephalosporin MICs is reduced ≥8-fold (i.e. by ≥3 doubling dilutions) by clavulanate. An exception is made for isolates of *K. oxytoca* considered to be K1 hyperproducers (see below) as these can give weak false positive results in clavulanate synergy testing with cefotaxime, cefepime or cefpirome, but not ceftazidime.

AmpC production is generally inferred if cefotaxime MIC is reduced ≥4-fold (i.e. by ≥2 doubling dilutions) by cloxacillin, but interpretation may be modified by reference to the whole antibiogram to allow for unusual or multiple mechanisms of resistance. (For example, in general, isolates with copious AmpC are more susceptible to cefepime/cefprome than to ceftazidime and cefotaxime, but derepressed AmpC in *Serratia* has little effect on ceftazidime.)

*K. oxytoca* that are highly resistant to piperacillin-tazobactam (≥128 mg/L), resistant to cefuroxime, no more than borderline resistant to cefotaxime and susceptible to ceftazidime will normally be interpreted as K1 hyperproducers and not as ESBL producers.

The Central Testing Laboratory will supply all the individual MICs obtained in the synergy tests for ESBL/AmpC/K1 detection to the BSAC in addition to the data for individual cephalosporins in the main dataset. The MIC recorded in the main dataset will generally be that measured originally, except when the initial value is censored (e.g. >16 mg/L) and the subsequent value is an exact result compatible with the original (e.g. 256 mg/L), in which case the subsequent exact result will be recorded.

### 7.2 Planned Additional Genotypic Testing

**CTX-M ESBLs**

Isolates inferred to have ESBLs (based on cephalosporin-clavulanate synergy) will be subjected to type-specific PCR for *bla*$_{CTX-M}$. If the isolate is resistant to either or both of cefotaxime and ceftazidime and if the cefotaxime MIC is higher than the ceftazidime MIC.

**AmpC**

*E. coli*, *Klebsiella* and *P. mirabilis* inferred to have AmpC-mediated resistance will be subjected to PCR for plasmid-mediated AmpC.

**Carbapenemases**

All carbapenem-non-susceptible Enterobacteriaceae except Proteaeae with only the borderline imipenem resistance (generally MICs 2-4 mg/L) inherent to the group will be examined for carbapenemase genes, by specific PCR or with DNA microarrays.

*Pseudomonas* with antibiograms suggesting carbapenemase production will be examined for the corresponding genes by specific PCR or DNA microarrays, as for Enterobacteriaceae. This will apply to isolates with high-level resistance to both imipenem (MIC >16 mg/L and >) and ceftazidime (MIC >64 mg/L); additional selection criteria may be developed if additional β-lactams are included in the test panel.

While carbapenem resistance remains sporadic, all isolates of *Acinetobacter* with antibiograms suggesting carbapenemase production will be examined for carbapenemase genes by specific PCR or DNA microarrays. In case of outbreaks, or if more than 25 isolates are candidates for carbapenemase testing, selection criteria may be developed and applied.

Confirmatory PCR will be used when the carbapenemase type is predictable from the antibiogram and arrays when it is not.

**mecA**

All *S. aureus* will be tested to detect the presence of the *mecA* gene (encoding PBP-2').

**mupA**

All *S. aureus* will be tested to detect the presence of the *mupA* gene (conferring high-level mupirocin resistance).

### 7.3 Additional Investigations of Exceptional Resistances and Resistance Clusters

**Unusual Resistances**

Exceptional resistances of public health importance will be investigated. In general, these are those that would have been investigated on the reference service of the PHE Antimicrobial Resistance and Healthcare Associated Infections Unit (AMRHAI) had the same isolate been submitted to AMRHAI by the collecting laboratory, for example:

- linezolid-resistant gram-positive bacteria (examined for G2576T, other rRNA mutations, or *cfr*)
- oxacillin-resistant *S. aureus* lacking *mecA* (examined for *mecC*).
Clusters
Typing will be undertaken on clusters of exceptionally resistant isolates. In general, these are those that would have been investigated by AMRHAI under its own remit for public health purposes had they been detected in other circumstances e.g. major clusters of carbapenemase-producers at a single hospital, or where unexpected phenotypes (e.g. colistin-resistant *Enterobacter*) are found to be geographically disseminated.

8 Quality Assurance
8.1 Internal Quality Control
The Central Testing Laboratory will supply data from internal controls including strain types, MICs and identification of test runs at the same time as the data from collected isolates.

8.2 External Quality Assessment
Isolates of known antimicrobial susceptibility will be supplied to the Central Testing Laboratory by an external laboratory for testing by the methods of this programme each year. Results from these tests will be supplied at the same time as the data from collected isolates.

9 Data Handling
There will be suitable safeguards to ensure that data is entered into the study records accurately, maintained securely, and disseminated in encrypted form only to authorised recipients.

The complete and final data will be supplied to the BSAC by the Central Testing Laboratory by 31st March following the isolate collection period.

The complete data for each isolate will include a listing to show its background information (hospital speciality etc.), MIC of each agent tested, information about the testing run numbers for each isolate (so that study results can be matched to control results and any runs producing unusual results can be identified) and information from any additional tests (e.g. MICs from ESBL synergy tests, results from molecular tests, interpretive readings of phenotypic tests, and all other data produced or received about the study isolates).

All other data related to the study such as the total number of lower respiratory isolates reported to PHE surveillance schemes by each laboratory and results for quality control isolates will be supplied at the same time as the data on study isolates.

Information on additional agents tested in the programme may be confidential to a sponsoring company. Confidential information will be seen by staff closely involved with the surveillance programme at the Central Testing Laboratory and the BSAC, but not included in listings for collecting laboratories or other sponsoring companies.

Information under the control of the BSAC (continuity group tests and information on sponsored agents where the sponsor has allocated control to the BSAC) will be widely disseminated. Each year, the BSAC will circulate the data line-listed by isolate to all full sponsors for that year, to each collecting laboratory for the isolates supplied by that laboratory, and in suitable summary form through the BSAC Resistance Surveillance Project website.

10 Collecting Laboratories
The set of collecting laboratories is selected to give good geographical coverage of the United Kingdom and Ireland, with a range of catchments (urban/rural, teaching/non-teaching hospitals, more/less socially deprived). The same set should contribute to both BSAC Resistance Surveillance Programmes (Bacteraemia and Respiratory).

The Central Testing Laboratory is responsible for the recruitment of replacement collecting laboratories, subject to approval by the BSAC. If a laboratory withdraws from the programme, it will be replaced using the following criteria as far as possible:

- in the same geographical area as the laboratory it is replacing, or in an area that is under-represented;
- of the same type as the laboratory it is replacing (e.g. district general hospital vs tertiary referral centre), or of a type that is under-represented;
- having the staff commitment and organisational capacity to contribute isolates reliably according to the protocol.

The 40 centres currently contributing (for the 2013/14 programme, as at 11th August 2014) are:

<table>
<thead>
<tr>
<th>Collecting Laboratory</th>
<th>City / Region</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buckinghamshire Healthcare NHS Trust</td>
<td>Aylesbury</td>
<td>England</td>
</tr>
<tr>
<td>North Devon District Hospital</td>
<td>Barnstable</td>
<td>England</td>
</tr>
<tr>
<td>Birmingham City Hospital</td>
<td>Birmingham</td>
<td>England</td>
</tr>
<tr>
<td>Bristol Royal Infirmary</td>
<td>Bristol</td>
<td>England</td>
</tr>
</tbody>
</table>
Collecting Laboratory | City / Region | Country
--- | --- | ---
North Bristol NHS Trust | Bristol | England
Addenbrooke’s Hospital | Cambridge | England
Coventry & Warwickshire Hospital | Coventry | England
Surrey and Sussex Healthcare NHS Trust | Crawley | England
Royal Derby Hospital | Derby | England
Eastbourne District General | Eastbourne | England
Gloucestershire Hospitals NHS Trust | Gloucester | England
Hull Royal Infirmary | Hull | England
Leicester Royal Infirmary | Leicester | England
Lewisham Healthcare NHS Trust | Lewisham | England
Path Links Pathology Service | Lincolnshire | England
Liverpool Clinical Laboratories | Liverpool | England
St Barts & The Royal London | London | England
Imperial College Healthcare NHS Trust | London | England
North Middlesex University Hospital NHS Trust | London | England
Wythenshawe Hospital | Manchester | England
Pathology for Wigan and Salford | Manchester | England
North Tees and Hartlepool NHS Trust | Middlesbrough | England
Freeman Hospital | Newcastle-upon-Tyne | England
Northampton General Hospital | Northampton | England
Peterborough and Stamford Hospitals NHS Trust | Peterborough | England
Northern General Hospital | Sheffield | England
Southampton General Hospital | Southampton | England
Royal Cornwall Hospital | Truro | England
New Cross Hospital | Wolverhampton | England
Worcestershire NHS Trust | Worcester | England
York Hospitals NHS Trust | York | England
Cork University Hospital | Cork | Ireland
Beaumont Hospital | Dublin | Ireland
St Vincent’s Hospital Dublin | Dublin | Ireland
University College Hospital Galway | Galway | Ireland
Ulster Hospital Dundonald | Belfast | N. Ireland
Royal Infirmary of Edinburgh | Edinburgh | Scotland
Southern General Hospital | Glasgow | Scotland
Raigmore Hospital | Inverness | Scotland
University Hospital of Wales | Cardiff | Wales

11 Protocol Amendments

11.1 Future Amendments
Amendments to this protocol can be made by agreement of the BSAC Extended Working Party on Resistance Surveillance.

11.2 Past Differences
The BSAC Respiratory Resistance Surveillance Programme has run since 1999, based on an original protocol dated 7th Feb 2000 with 20 collecting laboratories and collecting only from community-onset respiratory infections. A document of 21st Jan 2005 records amendments up to 2004/05. All previous amendments were incorporated into a revised protocol 24th Nov 2005 for 2005/6. The following edition, version 2.1 (22nd March 2006) remained in use up to 2007/08. It is the last protocol describing surveillance with up to 23 collecting laboratories for community-onset infections only and summarises changes between 1999/2000 and 2007/08.

From 2008/09, the surveillance was extended to include hospital-onset respiratory infections. Version 3.1 (9th Oct 2008) was the first protocol describing the programme with the extended scope. Later published versions were 3.1.1 and 3.2 (for 2008/09), and 3.3 and 3.3.1 (for 2009/10). The last protocol describing surveillance with up to 23 collecting laboratories was version 3.3.1 (1st Dec 2009); it records amendments made between the 2008/09 and 2009/10 isolate collections.
From 2010/11, the surveillance was extended with the intention of collecting isolates from 40 clinical laboratories. Version 4.1 was the first protocol describing the programme with the extended collecting network. Later published versions were 4.2 and 4.3 (for 2011/12), and 4.4 (for 2012/13). Version 4.4 records amendments made between the 2010/11 and 2012/13 collection periods.

Version 5.0 was the first protocol describing the programme following the consolidation of Central Testing Laboratory functions for both the Bacteraemia and Respiratory Resistance Surveillance Programmes at Public Health England, Colindale and applies to the 2013/14 respiratory isolate collection period.

Changes for version 5.0, 19th August 2013 (compared with version 4.4); reprinted 8th Oct 2013:

- Reworded several sections (e.g. sections 1 and 2) to harmonise with the protocol for the Bacteraemia Resistance Surveillance Programme
- Added accident & emergency (collected since about 2002) and respiratory medicine as new categories of hospital requesting specialities
- Updated the definition of the three care settings categories
- Updated the storage conditions in collecting laboratories
- Added the requirement to supply additional data included in the PHE scheme collecting respiratory isolates
- Updated the identification methods used by PHE in particular MALDI-ToF
- Harmonised the testing ranges for the core antimicrobial agents with those used in the Bacteraemia Programme
- Updated and clarified the testing conditions for ESBL and AmpC testing:
  - Use of cefepime in place of cefpirome for ESBL testing
  - Use of cefotaxime/cloxacillin combination for AmpC detection except when Etests are used, then use of cefotetan/cloxacillin combination
  - Use of Etests for AmpC and ESBL testing of Proteae
- Added carbapenemase testing (has been done before, but was not specified in protocol)
- Updated the list of collecting laboratories.

Changes for version 5.1, 29th May 2014 (compared with 5.0); still applies to 2013/14 collection period

- Amoxicillin-clavulanate to be tested with fixed 2 mg/L concentration of clavulanate, no longer 2:1 ratio.
- Amended testing ranges for H. influenzae, M. catarrhalis, removing open-ended commitments to test below 0.001 or above 256 mg/L, and for Acinetobacter.
- Replaced the phrases ‘community-acquired’ and ‘hospital-acquired’ with ‘community-onset’ and ‘hospital-onset’ throughout, but the definitions (≤48 and >48hours in hospital) are unchanged.
- Further update to collecting laboratories.

Changes for Respiratory Protocol 2013-14 v1 (19th August 2014) (compared with 5.1)

- Document name changed to include the isolate collection period; version numbers will restart at 1 for each new period
- Typographical corrections: CFU/ml (not /spot); community-onset S. pneumoniae (not S. aureus)
- Imipenem dropped for all previously-tested organisms and replaced by meropenem for Enterobacteriaceae, Pseudomonas, Acinetobacter.
- Cefuroxime dropped for Enterobacteriaceae.
- Tobramycin added for Enterobacteriaceae, Pseudomonas, Acinetobacter
- Carbenicillin added for Pseudomonas (with a view to a more targeted regime for future years).
- Nalidixic acid 30 µg disc test replaced by MIC testing (to establish a single test concentration to use in future years)
- Altered provision for further β-lactamase testing in Klebsiella oxytoca. Isolates with piperacillin-tazobactam MIC ≥128 mg/L will now undergo further tests irrespective of MICs for ceftazidime and cefotaxime, and these tests will include measurement of aztreonam and cefuroxime MICs in order to better detect K1 hyper-producers.